358:
If the nadir ANC < 500/μL for 10 days or more, or if the nadir platelet count at every time falls below 25,000/μL, then the doses of etoposide, doxorubicin and cyclophosphamide are reduced by 20% below the doses used in the previous cycle, but doxorubicin and etoposide should not be reduced below
500:
Wyndham H. Wilson, Michael L. Grossbard, Stefania
Pittaluga, Diane Cole, Deborah Pearson, Nicole Drbohlav, Seth M. Steinberg, Richard F. Little, John Janik, Martin Gutierrez, Mark Raffeld, Louis Staudt, Bruce D. Cheson, Dan L. Longo, Nancy Harris, Elaine S. Jaffe, Bruce A. Chabner, Robert Wittes,
321:
There is also an improved version of the regimen. In this version the chemotherapy dose varies from cycle to cycle depending on the patient's ability to tolerate chemotherapy and the degree of
344:
If the nadir ANC > 500/μL, then the doses of etoposide, doxorubicin, and cyclophosphamide for the next cycle are all increased by 20% over the doses used in the previous cycle.
329:
observed in this patient after each cycle. This approach is called "dose-adjusted EPOCH", or "DA-EPOCH" (DA-EPOCH-R, DA-R-EPOCH or R-DA-EPOCH are used when rituximab is included).
549:
486:
424:
569:
338:
Dose escalation above the starting doses in case of good patient's chemotherapy tolerability applies simultaneously to etoposide, doxorubicin and cyclophosphamide.
438:
Martin
Gutierrez, Bruce A. Chabner, Debra Pearson, Seth M. Steinberg, Elaine S. Jaffe, Bruce D. Cheson, Antonio Fojo, Wyndham H. Wilson (1 November 2000).
311:
502:
347:
If the nadir ANC < 500/μL on one or two blood checks, but ANC rises above 500 at the time of third check (i.e. the duration of
341:
Dose de-escalation below the starting doses in case of poor patient's chemotherapy tolerability applies to cyclophosphamide only.
141:
376:
W H Wilson, G Bryant, S Bates, A Fojo, R E Wittes, S M Steinberg, D R Kohler, E S Jaffe, J Herdt, B D Cheson (1 August 1993).
444:
382:
155:
503:"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy"
440:"Role of a Doxorubicin-Containing Regimen in Relapsed and Resistant Lymphomas: An 8-Year Follow-Up Study of EPOCH"
315:
31:
81:
27:
543:
480:
418:
23:
60:
524:
461:
399:
378:"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma"
314:
from the first day after the end of chemotherapy to the day of full blood count restoration (
516:
453:
391:
335:
Twice a week a full blood count with white blood cell count (WBC) differential is obtained.
326:
270:
261:
137:
507:
348:
91:
71:
563:
377:
162:
225:
87:
439:
355:
count is > 25,000/μL, then the dose for the next course will remain the same.
457:
322:
285:
281:
245:
241:
199:
151:
147:
127:
116:
112:
395:
303:
106:
520:
307:
209:
191:
98:
77:
53:
38:
528:
465:
403:
352:
63:
131:
123:
120:
94:
67:
102:
57:
158:
302:This regimen requires the use of prophylactic
154:: an anthracycline antibiotic that is able to
8:
548:: CS1 maint: multiple names: authors list (
485:: CS1 maint: multiple names: authors list (
423:: CS1 maint: multiple names: authors list (
351:is less than nine days), and the nadir of
359:the initial dose (dose in first course).
173:
368:
570:Chemotherapy regimens used in lymphoma
541:
478:
416:
126:, thereby preventing the formation of
84:from the group of epipodophyllotoxins;
310:complications, as well as the use of
119:: a vinca alkaloid that binds to the
7:
332:Dose change rules are as follows:
312:colony-stimulating factors (G-CSF)
49:.The R-EPOCH regimen consists of:
14:
293:IV continuous infusion over 24 h
253:IV continuous infusion over 24 h
217:IV continuous infusion over 24 h
66:, which has the ability to kill
142:alkylating antineoplastic agent
233:By mouth, twice a day (PO BID)
16:Intensive chemotherapy regimen
1:
501:Frank Balis (15 April 2002).
161:, damaging it and preventing
105:of both normal and malignant
445:Journal of Clinical Oncology
383:Journal of Clinical Oncology
41:. In this case it is called
458:10.1200/JCO.2000.18.21.3633
586:
396:10.1200/JCO.1993.11.8.1573
37:It is often combined with
521:10.1182/blood.V99.8.2685
82:topoisomerase inhibitor
32:non-Hodgkin's lymphoma
70:, be they normal or
24:chemotherapy regimen
282:Hydroxydaunorubicin
148:Hydroxydaunorubicin
452:(21): 3633–3642.
300:
299:
273:given over 15 min
577:
554:
553:
547:
539:
537:
535:
515:(8): 2685–2693.
497:
491:
490:
484:
476:
474:
472:
435:
429:
428:
422:
414:
412:
410:
390:(8): 1573–1582.
373:
327:thrombocytopenia
262:Cyclophosphamide
174:
150:, also known as
138:Cyclophosphamide
115:, also known as
22:is an intensive
585:
584:
580:
579:
578:
576:
575:
574:
560:
559:
558:
557:
540:
533:
531:
499:
498:
494:
477:
470:
468:
437:
436:
432:
415:
408:
406:
375:
374:
370:
365:
349:agranulocytosis
318:> 1000/μL).
172:
97:that can cause
17:
12:
11:
5:
583:
581:
573:
572:
562:
561:
556:
555:
492:
430:
367:
366:
364:
361:
298:
297:
294:
291:
288:
278:
277:
274:
267:
264:
258:
257:
254:
251:
248:
238:
237:
234:
231:
228:
222:
221:
218:
215:
212:
206:
205:
202:
197:
194:
188:
187:
184:
181:
178:
171:
170:Dosing regimen
168:
167:
166:
145:
135:
110:
92:glucocorticoid
85:
75:
30:of aggressive
15:
13:
10:
9:
6:
4:
3:
2:
582:
571:
568:
567:
565:
551:
545:
530:
526:
522:
518:
514:
510:
509:
504:
496:
493:
488:
482:
467:
463:
459:
455:
451:
447:
446:
441:
434:
431:
426:
420:
405:
401:
397:
393:
389:
385:
384:
379:
372:
369:
362:
360:
356:
354:
350:
345:
342:
339:
336:
333:
330:
328:
324:
319:
317:
313:
309:
305:
295:
292:
289:
287:
283:
280:
279:
275:
272:
268:
266:750 mg/m
265:
263:
260:
259:
255:
252:
250:0.4 mg/m
249:
247:
243:
240:
239:
235:
232:
229:
227:
224:
223:
219:
216:
213:
211:
208:
207:
203:
201:
198:
196:375 mg/m
195:
193:
190:
189:
185:
182:
179:
176:
175:
169:
164:
163:cell division
160:
157:
153:
149:
146:
143:
139:
136:
133:
129:
125:
122:
118:
114:
111:
108:
104:
100:
96:
93:
89:
86:
83:
79:
76:
73:
69:
65:
62:
59:
55:
52:
51:
50:
48:
44:
40:
35:
33:
29:
26:intended for
25:
21:
544:cite journal
532:. Retrieved
512:
506:
495:
481:cite journal
469:. Retrieved
449:
443:
433:
419:cite journal
407:. Retrieved
387:
381:
371:
357:
346:
343:
340:
337:
334:
331:
320:
301:
290:10 mg/m
230:60 mg/m
226:Prednisolone
214:50 mg/m
128:microtubules
88:Prednisolone
46:
42:
36:
19:
18:
323:neutropenia
306:to prevent
304:antibiotics
286:doxorubicin
246:vincristine
200:IV infusion
156:intercalate
152:doxorubicin
117:vincristine
107:lymphocytes
534:24 October
471:24 October
409:24 October
363:References
308:infectious
61:monoclonal
56:: an anti-
296:Days 1–4
256:Days 1–4
236:Days 1–5
220:Days 1–4
210:Etoposide
192:Rituximab
99:apoptosis
78:Etoposide
72:malignant
54:Rituximab
39:rituximab
28:treatment
564:Category
529:11929754
466:11054436
353:platelet
64:antibody
404:7687667
242:Oncovin
132:mitosis
124:tubulin
121:protein
113:Oncovin
95:hormone
68:B cells
47:EPOCH-R
43:R-EPOCH
527:
464:
402:
276:Day 5
204:Day 1
508:Blood
271:bolus
186:Days
140:: an
103:lysis
20:EPOCH
550:link
536:2020
525:PMID
487:link
473:2020
462:PMID
425:link
411:2020
400:PMID
325:and
183:Mode
180:Dose
177:Drug
130:and
101:and
90:: a
80:: a
58:CD20
517:doi
454:doi
392:doi
316:ANC
269:IV
159:DNA
45:or
566::
546:}}
542:{{
523:.
513:99
511:.
505:.
483:}}
479:{{
460:.
450:18
448:.
442:.
421:}}
417:{{
398:.
388:11
386:.
380:.
284::
244::
34:.
552:)
538:.
519::
489:)
475:.
456::
427:)
413:.
394::
165:.
144:;
134:;
109:;
74:;
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.